Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

IBRX - ImmunityBio Inc


IEX Last Trade
3.96
0.160   4.040%

Share volume: 2,275,939
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$3.80
0.16
4.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
26%
Profitability 22%
Dept financing 25%
Liquidity 49%
Performance 25%
Company vs Stock growth
vs
Performance
5 Days
-7.06%
1 Month
-25.19%
3 Months
-40.24%
6 Months
-13.19%
1 Year
139.39%
2 Year
2.86%
Key data
Stock price
$3.96
P/E Ratio 
-4.60
DAY RANGE
N/A - N/A
EPS 
-$0.95
52 WEEK RANGE
$1.25 - $10.53
52 WEEK CHANGE
$1.58
MARKET CAP 
2.751 B
YIELD 
N/A
SHARES OUTSTANDING 
696.533 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.46
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$2,024,018
AVERAGE 30 VOLUME 
$3,216,760
Company detail
CEO: Patrick Soon-Shiong
Region: US
Website: https://www.nantkwest.com/
Employees: 535
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.

Recent news